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Results
.
This meta-analysis of RCTs provides robust
evidence that DE is associated with an overall
significant 33% increase in the risk of MI. The risk
was principally identified when warfarin is used
as comparator (40% increase). In RCTs using the
150mg bid DE dose, a significant 44% overall
increased risk of MI was identified. No definitive
conclusion about the absence of the risk of MI
with the 110mg bid DE dose can be drawn at that
time. However, this increase risk has to be
tempered with the overall benefit of DE especially
in patients with NVAF. In conclusion, we suggest
that health care professionals and regulators
should consider additional risk minimization
strategy to identifiy vulnerable population and
prevent the risk in such patients.
Conclusions
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Discussion
Overall analyses
Dabigatran etexilate significantly increased the risk of MI by 33% versus any controls (► Figure 2 & Table 1). There was
a reduction in the risk of major bleeding and all-cause mortality compared to controls using the fixed effect model.
Compared to warfarin, the increase in the risk of MI still remained and even grown up (40% and 110% for the fixed and
random effect model, respectively) the reduction of major bleedings is statistically significant while the reduction in all-
cause mortality is not whatever the use of a fixed or random effect model (►Table 1).
Stratification by doses of dabigatran etexilate
The overall increased risk of MI with the 150mg bid dose is significant (44% and 79% with the fixed and random effect
model, respectively) but there was a 12% reduction of all-cause mortality. The reduction in major bleeding is non-
statistically significant (►Table 1). Versus warfarin, there was no statistically significant results for the 150mg bid dose
regimen, except for the risk of MI which was increased with the fixed effect model. However, we cannot rely on this result
since the heterogeneity excess 50% using the I2 statistic. For the 110mg bid dose regimen, there was no statistically
significant results but the increase risk of MI is of borderline significancy (p = 0.0057).
However, in terms of absolute risk, such an increased risk of MI should be tempered when compared to the outcomes of
stroke or systemic embolism, major bleeding and all-cause mortality. The results from the RE-LY trial showed that the
benefits of DE over warfarin outweigh the increase risk of MI. The risk difference was greatly in favor of DE regarding the
composite of stroke/systemic embolism, MI, major bleeding and all-cause mortality.
Dabigatran Etexilate and Risk of Myocardial Infarction, Major Bleedings 
and All-Cause Mortality: 
A Systematic Review and Meta-Analysis of Randomized Controlled Trials
ObjectivesBackground
In RE-LY, signal of an increased risk of myocardial
infarction (MI) with the use of dabigatran etexilate 110mg
bid and 150mg bid when compared to warfarin was pointed
out.1,2
This risk of MI was assessed in a previous meta-analysis of
7 non-inferiority randomized controlled trials (RCTs)
showing a significant 33% increase in MI.3 Unfortunately,
this analysis included the initial RE-LY publication and did
not take into account the additional events subsequently
reported in the latest RCTs. The question whether
dabigatran etexilate causes MI, or it is less efficacious than
warfarin for the prevention of such events remains
unanswered. There is a need to have robust evidence on
the potential increased risk of MI when dabigatran etexilate
is compared to other anticoagulants or placebo.
• Our primary aim was to perform an up-to-date meta-
analysis of RCTs comparing dabigatran etexilate with
active comparators or placebo to assess the effect of
this agent on MI risk as a primary objective.
• The outcome of major bleeding and all-cause
mortality was also assessed to provide global safety
and efficacy measure.
• Stratifications by comparators (enoxaparin, warfarin
or placebo) were performed. Additional analyses with
studies using the two licensed doses in European
Union for AF (150mg bid and 110mg bid) were also
provided.
Methods
We conducted searches of the published literature and a
clinical-trials registry maintained by the drug manufacturer
till 18th of October, 2013. Criteria for inclusion in our meta-
analysis included all RCTs and the availability of outcome
data for MI, major bleedings (MB) or all-cause mortality.
We referred to the definitions provided by the different
RCTs for the outcome adjudication. All methodologies were
performed according to the PRISMA Statement. The odds
ratio and 95% CI were calculated with the use of the Peto
method. The reported P values were two-sided. Statistical
heterogeneity across the various trials was tested using
Cochran’s Q statistic and quantified using the I2 value.
Funnel plots were constructed to assess publication bias.
Data were analysed with the use of Comprehensive Meta-
Analysis software, version 2.2.046.
Results
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Table 3: Risk of myocardial infarction, major bleeding and all-cause of death for the main analyses 
and stratification by dose and comparators
Figure 2: Forest plot of the included studies for the risk of 
myocardial infarction, major bleedings and all-cause mortality
(Fixed Effect Model analyses)
Study name Statistics for each study Peto odds ratio and 95%  CI
Peto Lower Upper 
odds ratio limit limit Z-Value p-Value
RE-LY 1,284 0,995 1,657 1,922 0,055
PETRO 3,189 0,056 182,637 0,561 0,574
RE-COVER 1,940 0,391 9,625 0,811 0,418
RE-MEDY 5,152 1,577 16,832 2,714 0,007
RE-NOVATE 0,709 0,292 1,726 -0,757 0,449
RE-MODEL 1,246 0,409 3,795 0,387 0,699
RE-NOVATE II 0,993 0,062 15,888 -0,005 0,996
RE-MOBILIZE 1,060 0,482 2,335 0,146 0,884
RE-DEEM 1,757 0,770 4,010 1,338 0,181
RE-SONATE 0,972 0,061 15,561 -0,020 0,984
RE-ALIGN 4,536 0,407 50,508 1,230 0,219
1,327 1,073 1,642 2,610 0,009
0,1 0,2 0,5 1 2 5 10
Favours Dabigatran (any dose) Favours Control Treatments
Myocardial Infarction
Major Bleeding
Study name Statistics for each study Peto odds ratio and 95% CI
Peto Lower Upper 
odds ratio limit limit Z-Value p-Value
RE-LY 0,866 0,764 0,983 -2,232 0,026
PETRO 3,203 0,182 56,375 0,796 0,426
RE-COVER 0,826 0,455 1,500 -0,627 0,531
RE-MEDY 0,526 0,277 0,997 -1,968 0,049
RE-NOVATE 1,055 0,603 1,848 0,189 0,850
RE-MODEL 1,060 0,481 2,337 0,145 0,884
RE-NOVATE II 1,541 0,678 3,506 1,032 0,302
RE-MOBILIZE 0,384 0,158 0,935 -2,107 0,035
RE-DEEM 1,747 0,547 5,582 0,941 0,346
RE-SONATE 7,196 0,450 115,202 1,395 0,163
BISTRO II 1,500 0,782 2,877 1,219 0,223
Fuji 1,729 0,304 9,846 0,617 0,537
RE-COVER II 0,687 0,359 1,314 -1,135 0,256
RE-ALIGN 1,676 0,410 6,855 0,719 0,472
0,884 0,792 0,987 -2,188 0,029
0,1 0,2 0,5 1 2 5 10
Favours Dabigatran (any dose) Favours Control Treatments
All-cause of mortality
Study name Statistics for each study Peto odds ratio and 95% CI
Peto Lower Upper 
odds ratio limit limit Z-Value p-Value
RE-LY 0,895 0,796 1,006 -1,860 0,063
RE-COVER 0,994 0,540 1,830 -0,018 0,986
RE-MEDY 0,891 0,462 1,720 -0,344 0,731
RE-NOVATE 4,483 0,819 24,531 1,730 0,084
RE-MODEL 0,999 0,090 11,036 -0,001 1,000
RE-NOVATE II 0,134 0,003 6,759 -1,005 0,315
RE-MOBILIZE 4,545 0,243 84,961 1,013 0,311
RE-DEEM 0,510 0,245 1,060 -1,804 0,071
RE-SONATE 0,131 0,008 2,102 -1,435 0,151
RE-COVER II 1,008 0,576 1,764 0,028 0,978
RE-ALIGN 0,220 0,020 2,455 -1,230 0,219
0,892 0,800 0,995 -2,048 0,041
0,1 0,2 0,5 1 2 5 10
Favours Dabigatran (any dose) Favours Control Treatments
Figure 1: PRISMA (Preferred Reporting Items for 
Systematic Reviews and Meta-Analysis) flow diagram of 
study selection.
When the heterogeneity, assessed by the I2 statistic is above
50%, it is preferable to refer to the random effect model
analysis
Tips
Peto Odds Ratio (95% CI) Heterogeneity 
Fixed-effect Model p-value Random Effect Model p-value I2 statistics Q test p-value
Myocardial Infarction
Any dose vs any control treatments 1.327 (1.073 - 1.642) 0.009 1.327 (1.073 - 1.642) 0.009 0 0.507
Any dose vs Enoxaparin 0.958 (0.574 - 1.599) 0.869 0.958 (0.574 - 1.599) 0.869 0 0.869
Any dose vs Warfarin 1.399 (1.095 - 1.786) 0.007 2.103 (1.026 - 4.314) 0.042 36.741 0.176
Any dose vs Placebo 1.674 (0.759 - 3.693) 0.202 1.674 (0.759 - 3.693) 0.202 0 0.689
150mg bid vs any control treatments 1.441 (1.092 - 1.901) 0.010 1.794 (1.042 - 3.089) 0.035 29.128 0.227
150mg bid vs Enoxaparin NA NA NA NA
150mg bid vs Warfarin 1.412 (1.060 - 1.882) 0.018 2.070 (0.833 - 5.143) 0.117 60.943 0.077
150mg bid vs Placebo 1.885 (0.656 - 5.413) 0.239 1.885 (0.656 - 5.413) 0.239 0 0.613
110mg bid vs any control treatments 1.326 (0.991 - 1.774) 0.057 1.326 (0.991 - 1.774) 0.057 0 0.760
110mg bid vs Enoxaparin NA NA NA NA
110mg bid vs Warfarin NA NA NA NA
110mg bid vs Placebo NA NA NA NA
Major Bleeding
Any dose vs any control treatments 0.884 (0.792 - 0.987) 0.029 0.927 (0.751 - 1.145) 0.483 24.232 0.192
Any dose vs Enoxaparin 1.068 (0.777 - 1.468) 0.685 1.044 (0.681 - 1.598) 0.845 41.876 0.142
Any dose vs Warfarin 0.849 (0.754 - 0.956) 0.007 0.849 (0.754 - 0.956) 0.007 0 0.495
Any dose vs Placebo 2.031 (0.816 - 5.056) 0.128 2.031 (0.816 - 5.056) 0.128 0 0.639
150mg bid vs any control treatments 0.923 (0.811 - 1.051) 0.228 0.921 (0.668 - 1.269) 0.615 42.907 0.105
150mg bid vs Enoxaparin NA NA NA NA
150mg bid vs Warfarin 0.895 (0.785 - 1.022) 0.101 0.840 (0.674 - 1.047) 0.122 19.506 0.292
150mg bid vs Placebo 2.857 (0.711 - 11.473) 0.139 2.857 (0.711 - 11.473) 0.139 0 0.450
110mg bid vs any control treatments 0.817 (0.707 - 0.946) 0.007 1.355 (0.375 - 4.902) 0.643 77.276 0.036
110mg bid vs Enoxaparin NA NA NA NA
110mg bid vs Warfarin NA NA NA NA
110mg bid vs Placebo NA NA NA NA
All-Cause Death
Any dose vs any control treatments 0.892 (0.800 - 0.995) 0.041 0.885 (0.719 - 1.090) 0.252 11.026 0.339
Any dose vs Enoxaparin 2.238 (0.678 - 7.389) 0.186 2.143 (0.598 - 7.672) 0.242 8.532 0.350
Any dose vs Warfarin 0.900 (0.805 - 1.005) 0.061 0.900 (0.805 - 1.005) 0.061 0 0.813
Any dose vs Placebo 0.467 (0.230 - 0.947) 0.035 0.467 (0.230 - 0.947) 0.035 0 0.354
150mg bid vs any control treatments 0.881 (0.779 - 0.997) 0.045 0.881 (0.779 - 0.997) 0.045 0 0.636
150mg bid vs Enoxaparin NA NA NA NA
150mg bid vs Warfarin 0.894 (0.789 - 1.013) 0.078 0.894 (0.789 - 1.013) 0.078 0 0.955
150mg bid vs Placebo 0.475 (0.208 - 1.088) 0.078 0.475 (0.208 - 1.088) 0.078 0 0.341
110mg bid vs any control treatments 0.896 (0.785 - 1.022) 0.103 0.743 (0.403 - 1.371) 0.343 57.176 0.126
110mg bid vs Enoxaparin NA NA NA NA
110mg bid vs Warfarin NA NA NA NA
110mg bid vs Placebo NA NA NA NA
